Blood test can detect single lung cancer calls using infrared technique
December 16, 2025
A UK research team has developed a pioneering blood test that could change the way lung cancer is detected and monitored.
A UK research team has developed a pioneering blood test that could change the way lung cancer is detected and monitored.
ALS is a debilitating paralytic disease characterized as the death of upper and lower motor neurons. Fortunately, ALS is relatively rare, with an incidence rate of 1.6 per 100,000 adults, resulting in about 30,000 cases in the United States at any one time.
A new artificial intelligence model could help design antibodies that better protect the body against viruses and disease. The AI model, known as ImmunoMatch, can predict and identify correct protein pairings within antibodies, potentially helping to strengthen the immune system. The research was conducted by a team from the University of Surrey and University College London and is published in Nature Methods.
BONADUZ, Switzerland, Dec. 16, 2025 /PRNewswire/ — Hamilton today announced the launch of GlucoSense, a breakthrough in bioprocess analytics that introduces the first reusable, in situ glucose sensor designed to deliver continuous, real-time measurements directly inside cell culture bioreactors.
Zephyrus Innovations (Zephyrus), a privately-owned medical device company designing and manufacturing safety syringes and Closed System Transfer Devices (CSTDs), today announces that it has received product 510(k) Marketing Clearance from the US Food and Drug Administration (“FDA”) for its VaporShield ™ CSTD.
New production capacity strengthens MPM Medical’s position as a leading U.S. manufacturer and follows the company’s recent launch of collagen at-home wound care kits
PITTSBURGH, Dec. 16, 2025 /PRNewswire/ — Net Health today announced the platform integration of MolecuLight with Tissue Analytics, its AI-powered mobile wound imaging and analytics solution.
IRVINE, Calif., Dec. 16, 2025 /PRNewswire/ — OrthAlign, Inc., a global leader in surgical navigation technologies, today announced the expansion of its Lantern® Hip platform to include support for posterior-based approaches in total hip arthroplasty (THA).
Using new molecules that block an immune checkpoint, researchers showed they could stimulate a strong anti-tumor immune response.
According to a US pivotal study, the device’s sensitivity has been reported at more than 76% on all specimens.